10-Q 1 d813401d10q.htm 10-Q 10-Q
falseQ10001613780--12-31American Depositary Shares, each representing one-half of one ordinary share, nominal value €0.10 per share00-0000000 0001613780 2023-12-31 0001613780 2024-03-31 0001613780 2023-01-01 2023-03-31 0001613780 2024-01-01 2024-03-31 0001613780 2024-05-07 0001613780 2023-03-31 0001613780 2022-12-31 0001613780 dbvt:ExpensesByFunctionMember 2024-01-01 2024-03-31 0001613780 dbvt:ExpensesByNatureMember 2024-01-01 2024-03-31 0001613780 dbvt:PrefundedWarrantsMember 2024-01-01 2024-03-31 0001613780 dbvt:NonemployeewarrantsMember 2024-01-01 2024-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001613780 dbvt:RentExpensesMember 2024-01-01 2024-03-31 0001613780 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0001613780 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001613780 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2024-01-01 2024-03-31 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2024-01-01 2024-03-31 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2024-01-01 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001613780 dei:AdrMember 2024-01-01 2024-03-31 0001613780 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001613780 dbvt:OtherAssetMember 2023-12-31 0001613780 us-gaap:RealEstateMember 2023-12-31 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2023-12-31 0001613780 dbvt:TaxLiabilitiesMember 2023-12-31 0001613780 dbvt:OtherDebtsMember 2023-12-31 0001613780 dbvt:ExpensesByFunctionMember 2023-01-01 2023-03-31 0001613780 dbvt:ExpensesByNatureMember 2023-01-01 2023-03-31 0001613780 dbvt:PrefundedWarrantsMember 2023-01-01 2023-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001613780 dbvt:NonemployeewarrantsMember 2023-01-01 2023-03-31 0001613780 dbvt:RentExpensesMember 2023-01-01 2023-03-31 0001613780 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001613780 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001613780 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001613780 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001613780 us-gaap:CommonStockMember 2024-03-31 0001613780 us-gaap:RealEstateMember 2024-03-31 0001613780 dbvt:OtherAssetMember 2024-03-31 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2024-03-31 0001613780 dbvt:OtherDebtsMember 2024-03-31 0001613780 dbvt:TaxLiabilitiesMember 2024-03-31 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2024-03-31 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2024-03-31 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2024-03-31 0001613780 dbvt:ShareCapitalMember 2024-03-31 0001613780 dbvt:AmericanDepositarySharesMember dbvt:AtTheMarketMember 2022-05-01 2022-05-31 0001613780 dbvt:PrivateInvestmentInPublicEquityMember 2022-01-01 2022-06-30 0001613780 srt:MaximumMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 2020-01-31 0001613780 srt:MinimumMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 2020-01-31 0001613780 dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 2020-01-31 0001613780 us-gaap:CommonStockMember 2023-03-31 0001613780 dbvt:ComfortChildrenSafetyStudyMember srt:MaximumMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2023-07-31 2023-07-31 0001613780 dbvt:ComfortChildrenSafetyStudyMember srt:MinimumMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2023-07-31 2023-07-31 0001613780 dbvt:ComfortToddlersSafetyStudyMember srt:MaximumMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2023-07-31 2023-07-31 0001613780 dbvt:ComfortToddlersSafetyStudyMember srt:MinimumMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2023-07-31 2023-07-31 0001613780 dbvt:ComfortToddlersSafetyStudyMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2023-07-31 2023-07-31 0001613780 dbvt:ComfortChildrenSafetyStudyMember dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2023-07-31 2023-07-31 0001613780 us-gaap:RetainedEarningsMember 2023-12-31 0001613780 us-gaap:TreasuryStockCommonMember 2023-12-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001613780 us-gaap:CommonStockMember 2023-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2023-12-31 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2023-12-31 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2023-12-31 0001613780 dbvt:BSAWarrantsMember 2023-12-31 0001613780 dbvt:BSAWarrantsMember 2024-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001613780 us-gaap:RetainedEarningsMember 2024-03-31 0001613780 us-gaap:TreasuryStockCommonMember 2024-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2023-12-31 0001613780 us-gaap:EmployeeStockOptionMember 2024-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001613780 us-gaap:RetainedEarningsMember 2022-12-31 0001613780 us-gaap:TreasuryStockCommonMember 2022-12-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001613780 us-gaap:CommonStockMember 2022-12-31 0001613780 us-gaap:TreasuryStockCommonMember 2023-03-31 0001613780 us-gaap:RetainedEarningsMember 2023-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 iso4217:USD xbrli:shares utr:Year xbrli:pure utr:Month iso4217:EUR iso4217:EUR xbrli:shares dbvt:Candidates iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
or
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
to
Commission file number
001-36697
 
 
DBV TECHNOLOGIES S.A.
(Exact name of registrant as specified in its charter)
 
 
 
France
 
Not applicable
State or other jurisdiction of
incorporation or organization
 
(I.R.S. Employer
Identification No.)
177-181 avenue Pierre
Brossolette
Montrouge 92120 France
 
N/A
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code +33 1 55 42 78 78
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
American Depositary Shares, each representing
one-half
of one ordinary share, nominal value
€0.10 per share
 
DBVT
 
The Nasdaq Stock Market LLC
Ordinary shares, nominal value €0.10 per share*
 
n/a
 
The Nasdaq Stock Market LLC
 
*
Not for trading, but only in connection with the registration of the American Depositary Shares.
Securities registered pursuant to section 12(g) of the Act: None.
 
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer  
Non-accelerated
filer
     Smaller reporting company  
Emerging growth company       
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Act). Yes ☐ No 
As of May 7, 2024, the registrant had 96,434,369
      
ordinary shares, nominal value €0.10 per share, outstanding including treasury shares.
 
 
 


Table of contents

 

Part I

  Financial information      3  

Item 1

  Condensed Consolidated Statements of Financial Position (Unaudited) as of March 31, 2024 and December 31, 2023      3  
  Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the Three Months Ended March 31, 2024 and 2023      4  
  Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2024 and 2023      5  
  Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) for the Three Months Ended March 31, 2024 and 2023      6  
  Notes to the Condensed Consolidated Financial Statements (Unaudited)      7  

Item 2

  Management’s Discussion and Analysis of Financial Condition and Results of Operations      18  

Item 3

  Quantitative and Qualitative Disclosures About Market Risk      23  

Item 4

  Controls and Procedures      23  

Part II

  Other Information      24  

Item 1

  Legal Proceedings      24  

Item 1A

  Risk Factors      24  

Item 2

  Unregistered Sales of Equity Securities and Use of Proceeds      24  

Item 3

  Defaults Upon Senior Securities      24  

Item 4

  Mine Safety Disclosures      24  

Item 5

  Other Information      24  

Item 6

  Exhibits      25  

Unless the context otherwise requires, we use the terms “DBV”, “DBV Technologies,” the “Company,” “we,” “us” and “our” in this Quarterly Report on Form 10-Q, or Quarterly Report, to refer to DBV Technologies S.A. and, where appropriate, its consolidated subsidiaries. “Viaskin”, “EPIT” and our other registered and common law trade names, trademarks and service marks are the property of DBV Technologies S.A. or our subsidiaries. All other trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Quarterly Report may be referred to without the ® and  symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.

 


558800010174
SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS.
This Quarterly Report contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact, about, among other things:
 
   
our expectations regarding the timing or likelihood of regulatory filings and approvals, including with respect to our anticipated
re-submission
of a Biologics License Application, or a BLA, for Viaskin
TM
Peanut to the U.S. Food and Drug Administration, or the FDA;
 
   
the design, timing and anticipated results of interactions with regulatory agencies;
 
   
the initiation, timing, progress and results of our
pre-clinical
studies and clinical trials, and our research and development programs;
 
   
the sufficiency of existing capital resources;
 
   
our business model and our other strategic plans for our business, product candidates and technology;
 
   
our ability to manufacture clinical and commercial supplies of our product candidates and comply with regulatory requirements related to the manufacturing of our product candidates;
 
   
our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize Viaskin Peanut and/or our other product candidates, if approved;
 
   
the commercialization of our product candidates, if approved;
 
   
our expectations regarding the potential market size and the size of the patient populations for Viaskin Peanut and/or
our
other product candidates, if approved, and our ability to serve such markets;
 
   
the pricing and reimbursement of our product candidates, if approved;
 
   
the rate and degree of market acceptance of Viaskin Peanut and/or our other product candidates, if approved, by physicians, patients, third-party payors and others in the medical community;
 
   
our ability to advance product candidates into, and successfully complete, clinical trials;
 
   
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;
 
   
estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
 
   
the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;
 
   
our ability to maintain and establish collaborations or obtain additional funding;
 
   
our financial performance;
 
   
developments relating to our competitors and our industry, including competing therapies; and
 
   
other risks and uncertainties, including those listed under the caption “Risk Factors.”
Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward-looking statement. These risks, uncertainties and other factors are described in greater detail under the caption “Risk Factors” in Part I. Item 1A of our Annual Report on Form
10-K
for the year ended December 31, 2023, filed with the Securities and Exchange Commission, or the SEC on March 7, 2024. As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. Undue reliance should not be placed on any forward-looking statement. We qualify all of our forward-looking statements by these cautionary statements.
 
1

In addition, any forward-looking statement in this Quarterly Report, including statements that “we believe” and similar statements, reflect our beliefs and opinions on the relevant subject and represents our views only as of the date of this Quarterly Report and should not be relied upon as representing our views as of any subsequent date. These statements are based upon information available to us as of the date of this Quarterly Report and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.
 
2

Part I - Financial Information
Item 1. Financial Statements
DBV Technologies S.A.
Condensed Consolidated Statements of Financial Position (unaudited)
(amounts in thousands, except share and per share data)
 
           
March 31,
   
December 31,
 
    
Note
    
2024
   
2023
 
Assets
       
Current assets:
       
Cash and cash equivalents
  
 
3
 
   $ 101,525     $ 141,367  
Other current assets
  
 
4
 
     18,037       17,548  
     
 
 
   
 
 
 
Total current assets
     
 
119,562
 
 
 
158,915
 
Property, plant, and equipment, net
        12,913       12,623  
Right-of-use
assets related to operating leases
  
 
5
 
     6,551       5,247  
Intangible assets
        52       58  
Other
non-current
assets
        6,818       6,144  
     
 
 
   
 
 
 
Total
non-current
assets
     
 
26,334
 
 
 
24,071
 
     
 
 
   
 
 
 
Total Assets
     
$
145,895
 
 
$
182,986
 
     
 
 
   
 
 
 
Liabilities and shareholders’ equity
       
Current liabilities:
       
Trade payables
  
 
6
 
   $ 18,076     $ 23,302  
Short-term operating leases
  
 
5
 
     232       1,144  
Current contingencies
  
 
9
 
     3,153       3,959  
Other current liabilities
  
 
6
 
     5,023       8,934  
     
 
 
   
 
 
 
Total current liabilities
     
 
26,483
 
 
 
37,339
 
     
 
 
   
 
 
 
Long-term operating leases
  
 
5
 
     6,793       4,526  
Non-current
contingencies
  
 
9
 
     965       935  
Other
non-current
liabilities
  
 
6
 
            
     
 
 
   
 
 
 
Total
non-current
liabilities
     
 
7,758
 
 
 
5,461
 
     
 
 
   
 
 
 
Total Liabilities
     
$
34,241
 
 
$
42,799
 
     
 
 
   
 
 
 
Shareholders’ equity:
       
Ordinary shares, €0.10 par value; 96,434,369 and 96,431,770 shares authorized, and issued as of March 31, 2024 and December 31, 2023, respectively
      $ 10,972     $ 10,972  
Additional
paid-in
capital
        379,426       377,468  
Treasury stock, 262,644 and 222,988 ordinary shares as of March 31, 2024 and December 31, 2023, respectively, at cost
        (1,325     (1,263
Accumulated deficit
        (266,207      (238,862 
Accumulated other comprehensive income
        683       742  
Accumulated currency translation effect
        (11,897     (8,871
     
 
 
   
 
 
 
Total Shareholders’ equity
  
 
7
 
  
$
111,654
 
 
$
140,187
 
     
 
 
   
 
 
 
Total Liabilities and Shareholders’ equity
     
$
145,895
 
 
$
182,986
 
     
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
3

DBV Technologies S.A.
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
(amounts in thousands, except share and per share data)
 
           
Three Months Ended

March 31,
 
    
Note
    
2024
   
2023
 
Operating income
  
 
10
 
  
$
1,407
 
 
$
2,194
 
Operating expenses
       
Research and development expenses
  
 
11
 
     (21,403     (16,037
Sales and marketing expenses
  
 
11
 
     (758     (434
General and administrative expenses
  
 
11
 
     (7,804     (6,889
     
 
 
   
 
 
 
Total Operating expenses
     
 
(29,964
 
 
(23,359
     
 
 
   
 
 
 
Loss from operations
     
 
(28,558
 
 
(21,165
     
 
 
   
 
 
 
Financial income(expenses)
  
 
13
 
     1,261       605  
     
 
 
   
 
 
 
Loss before taxes
     
 
(27,297
 
 
(20,561
     
 
 
   
 
 
 
Income tax (expense)
        (48      
     
 
 
   
 
 
 
Net loss
     
$
(27,345
 
$
(20,561
     
 
 
   
 
 
 
Foreign currency translation differences, net of taxes
        (3,026     3,666  
Actuarial gains (losses) on employee benefits, net of taxes
        (59     (82
     
 
 
   
 
 
 
Total comprehensive loss
     
$
(30,429
 
$
(16,977
     
 
 
   
 
 
 
Basic/diluted Net loss per share attributable to shareholders
  
 
15
 
  
$
(0.28
 
$
(0.22
Weighted average shares outstanding used in computing per share amounts:
        96,176,057       93,970,598  
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
4

DBV Technologies S.A.
Condensed Consolidated Statements of Cash Flows (unaudited)
(amounts in thousands)
 
           
Three Months Ended March 31,
 
    
Notes
    
2024
   
2023
 
Net loss for the period
     
$
(27,345
 
$
(20,561
Adjustments to reconcile net loss to net cash flow provided by (used in) operating activities:
       
Depreciation, amortization and accrued contingencies
        53       (228
Retirement pension obligations
        (8     (35
Expenses related to share-based payments
  
 
8
 
     1,958       1,632  
Other elements
                       
Changes in operating assets and liabilities:
       
Decrease (increase) in other current assets
        (835     (3,098
(Decrease) increase in trade payables
        (4,805     4,478  
(Decrease) increase in other current and
non-current
liabilities
        (3,765     (2,989
Change in operating lease liabilities and right of use assets
        56       (42
Net cash flow provided by (used in) operating activities
     
 
(34,692
 
 
(20,841
     
 
 
   
 
 
 
Cash flows provided by (used in) investing activities:
       
Acquisitions of property, plant, and equipment
        (1,335     (111
Proceeds from property, plant, and equipment dispositions
                       
Acquisitions of
non-current
financial assets
        (858      
Proceeds from
non-current
financial assets dispositions
        62       153  
     
 
 
   
 
 
 
Net cash flows provided by (used in) investing activities
     
 
(2,132
 
 
42
 
     
 
 
   
 
 
 
Cash flows provided by (used in) financing activities:
       
(Decrease) increase in conditional advances
                       
Treasury shares
        (62     (14
     
 
 
   
 
 
 
Net cash flows provided by (used in) financing activities
     
 
(62
 
 
(14
     
 
 
   
 
 
 
Effect of exchange rate changes on cash and cash equivalents
        (2,957     3,909  
     
 
 
   
 
 
 
Net increase (decrease) in cash and cash equivalents
     
 
(39,842
 
 
(16,905
     
 
 
   
 
 
 
Net Cash and cash equivalents at the beginning of the period
        141,367       209,194  
     
 
 
   
 
 
 
Net cash and cash equivalents at the end of the period
  
 
3
 
  
$
101,525
 
 
$
192,289
 
     
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
5

DBV Technologies S.A.
Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited)
(amounts in th
ousands, except share
and per share data)
 
    
Ordinary shares
                                      
    
Number of

Shares
    
Amount
    
Additional

paid-in

capital
   
Treasury

stock
   
Accumulated

deficit
   
Accumulated

other

comprehensive

income (loss)
   
Accumulated

currency

translation

effect
   
Total

Shareholders’

Equity
 
Balance at January 1, 2023
  
 
94,137,145
 
  
$
 10,720
 
  
$
458,221
 
 
$
(1,109
 
$
(259,578
 
$
781
 
 
$
(14,581
 
$
194,453
 
Net (loss)
     —         —         —        —        (20,561     —        —        (20,561
Other comprehensive income (loss)
     —         —         —        —        —        (82     3,666       3,584  
Issuance of ordinary shares
    
10 174
       1        (1     —        —        —        —         
Treasury shares
     —         —         —        (14     —        —        —        (14
Share-based payments
     —         —         1,632       —        —        —        —        1,632  
  
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance at March 31, 2023
  
 
94,147,319
 
  
$
10,721
 
  
$
459,852
 
 
$
(1,123
 
$
(280,138
 
$
698
 
 
$
(10,915
 
$
179,094
 
 
    
Ordinary shares
                                      
    
Number of

Shares
    
Amount
    
Additional

paid-in

capital
   
Treasury

stock
   
Accumulated

deficit
   
Accumulated

other

comprehensive

income (loss)
   
Accumulated

currency

translation

effect
   
Total

Shareholders’

Equity
 
Balance at January 1, 2024
  
 
96,431,770
 
  
$
10,972
 
  
$
377,468
 
 
$
(1,263
 
$
(238,862
 
$
742
 
 
$
(8,871
 
$
140,187
 
Net (loss)
     —         —         —        —        (27,345     —        —        (27,345
Other comprehensive income (loss)
     —         —         —        —        —        (59     (3,026     (3,084
Issuance of ordinary shares
     2,599        3        (3     —        —        —        —         
Treasury shares
     —         —         —        (62     —        —        —        (62
Share-based payments
     —         —         1,958       —        —        —        —        1,958  
  
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance at March 31, 2024
  
 
96,434,369
 
  
$
10,972
 
  
$
379,426
 
 
$
(1,325
 
$
(266,207
 
$
683
 
 
$
(11,897
 
$
111,654
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
6

NOTES TO THE CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
Note 1: The Company
Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies” or the “Company”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Basis of Presentation
The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.
The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form
10-K
filed with the SEC on March 7, 2024 (the “Annual Report”). The condensed consolidated statement of financial position as of December 31, 2023 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2023.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2024, or any other future period.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates.
On an
on-going
basis, management evaluates its estimates, primarily those related to: (1) evaluation of costs and measure of progress of wind-down activities resulting from the termination of the collaboration agreement with Nestlé Health Science, (2) research tax credits, (3) assumptions used in the valuation of right of use assets—operating lease, (4) impairment of
right-of-use
assets related to leases and property, plant and equipment, (5) recoverability of the Company’s net deferred tax assets and related valuation allowance, (6) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan, (7) estimate of contingencies
,
and (8) estimate of employee benefits obligations.
Going Concern
These Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, substantial doubt about the Company’s ability to continue as a going concern exists.
Since its inception, the Company has primarily funded its operations with equity financings, and, to a lesser extent, public assistance aimed at supporting innovation and payments associated with research tax credits (Crédit d’Impôt Recherche). The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.
Following receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) in connection with its BLA for Viaskin Peanut, in August 2020, the Company scaled down its other clinical programs and
pre-clinical
spend to focus on Viaskin Peanut. The Company also initiated a global restructuring plan in June 2020 to provide operational latitude to progress the clinical development and regulatory review of Viaskin Peanut in the United States and European Union.
 
7

In January 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request the Company submitted in October 2020 following the CRL. In order to respond to the FDA’s requests and recommendations, the Company defined parallel workstreams primarily in order to generate the
6-month
safety and adhesion clinical data to assess a modified Viaskin Peanut patch and demonstrate the equivalence in allergen uptake between the current and modified patches in the intended patient population.
Following the submission of the adhesion study’s protocol to the FDA, the Company received an Advice/ Information Request letter from the FDA in October 2021, requesting a stepwise approach to the modified Viaskin patch development program and provided partial feedback on this protocol.
In December 2021, the Company decided not to pursue the sequential approach to the development plans for Viaskin Peanut as requested by the FDA in the October 2021 feedback and announced its plan to initiate a pivotal Phase 3 clinical study for a modified Viaskin Peanut patch (mVP) in children in the intended patient population. The Company considers this approach as the most straightforward approach to demonstrate effectiveness, safety, and improved in vivo adhesion of the modified Viaskin Peanut system. After receiving approval from the FDA for its change in strategy, the protocol for the new Phase 3 pivotal study of the modified Viaskin Peanut (mVP) patch was completed at the end of February 2022 and has been prepared for FDA submission.
In May 2022, the Company established an
At-The-Market
(“ATM”) program allowing to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $100 million of American Depositary Shares (“ADSs”). The Company’s intent is to use the net proceeds, if any, of sales of ADSs issued under the program, together with its existing cash and cash equivalents, primarily for activities associated with potential approval and launch of Viaskin Peanut, as well as to advance the development of the Company’s product candidates using its Viaskin Platform and for working capital and other general corporate purposes.
In June 2022, the Company announced that its pivotal Phase 3 trial EPITOPE, assessing the safety and efficacy of Viaskin Peanut treatment of peanut-allergic toddlers ages 1 to 3 years, met its primary endpoint, with a statistically significant treatment effect. The Company also indicated continuing productive dialogue with the FDA on the protocol design of VITESSE, a pivotal Phase 3 trial of the modified Viaskin Peanut patch in peanut- allergic children ages 4 to 7 years.
During the same month, the Company announced private placement financing (“PIPE”) amounting to $194 million.
In September 2022, after announcing the initiation of the VITESSE clinical trial, the Company received a partial clinical hold letter from the FDA on its VITESSE Phase 3 clinical study. Within the FDA’s communication, the modifications address design elements, including the statistical analysis of adhesion, minimum daily wear time and technical alignments in methods of categorizing data, to meet study objectives as well as the total number of trial participants on active treatment.
On December 23, 2022, the Company announced the FDA lifted the partial clinical hold and confirmed the Company satisfactorily addressed all clinical hold issues. The FDA stated that the VITESSE phase 3 clinical study may proceed with the revised trial protocol. On March 7, 2023, the Company announced that the first patient was screened in the VITESSE study. Screening of the last patient is anticipated by Q3 2024.
The company has incurred operating losses and negative cash flows from operations since inception. As of the date of the filing, the Company’s available cash and cash equivalents are not projected to be sufficient to support its operating plan for at least the next 12 months. As such, there is substantial doubt regarding the Company’s ability to continue as a going concern.
Based on our current operations, as well as our plans and assumptions, we expect that our balance of cash and cash equivalents of $101.5 million as of March 31, 2024 will be sufficient to fund our operations until December 31, 2024.
The Company intends to seek additional capital as it prepares for the launch of Viaskin Peanut, if approved, and continues other research and development efforts. The Company will require substantial additional capital to fund its research and development and ongoing operating expenses. These capital requirements are expected to be funded through debt and equity offerings prior to December 31, 2024. The Company may seek to finance its future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of
non-dilutive
financings.
The Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets due to any future pandemics, epidemics or global health crises and conflict in Ukraine or other global political or military crises. The
COVID-19
pandemic and conflict in Ukraine caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to the Company, including reduced ability to raise additional capital when needed or on acceptable terms, if at all.
 
8

If the Company is not successful in its financing objectives, the Company could have to scale back its operations, notably by delaying or reducing the scope of its research and development efforts or obtain financing through arrangements with collaborators or others that may require the Company to relinquish rights to its product candidates that the Company might otherwise seek to develop or commercialize independently.
These Condensed Consolidated Financial Statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company was unable to continue as a going concern.
Accounting Pronouncements recently adopted
There have been no recently issued accounting standards adopted during the period which had a material impact on the Company’s financial statements.
There are no recently issued accounting standards that are expected to have a material impact on our results of operations, financial condition, or cash flows.
Accounting Pronouncements issued not yet adopted
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.
Note 2: Significant Events and Transactions
Clinical programs
United States Regulatory History and Current Status
In January 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request the Company submitted in October 2020 following
receipt of 
the Complete Response Letter. The FDA agreed with its position that a modified Viaskin Peanut patch should not be considered as a new product entity provided the occlusion chamber of the current Viaskin Peanut patch and the peanut protein dose of 250 µg (approximately 1/1000 of one peanut) remains unchanged and performs in the same way it has performed previously. In order to confirm the consistency of efficacy data between the existing and a modified patch,
 the
FDA requested an assessment comparing the uptake of allergen (peanut protein) between the patches in peanut allergic children ages
4-11.
The Company named that assessment EQUAL, which stands for Equivalence in Uptake of ALlergen. The FDA also recommended conducting a
6-month,
well-controlled safety and adhesion trial to assess a modified Viaskin Peanut patch in the intended patient population. The Company later named this study STAMP, which stands for Safety, Tolerability, and Adhesion of Modified Patches.
In March 2021, the Company commenced CHAMP (Comparison of adHesion Among Modified Patches), a Phase 1 trial in healthy adult volunteers to evaluate the adhesion of five modified Viaskin Peanut patches. The Company completed CHAMP in the second quarter of 2021. All modified Viaskin Peanut patches demonstrated better adhesion performance as compared to the then-current Viaskin Peanut patch, and the Company then selected two modified patches that performed the best out of the five modified patches studied for further development. The Company then selected the circular patch for further development, which is larger in size relative to the current patch and circular in shape.
In May 2021, the Company submitted its proposed STAMP protocol to the FDA, and on October 14, 2021, the Company received an Advice/Information Request letter from the FDA. In this letter, the FDA requested a stepwise approach to the modified Viaskin patch development program and provided partial feedback on the STAMP protocol. Specifically, the FDA requested that the Company conduct allergen uptake comparison studies (i.e., ‘EQUAL in Adults’, EQUAL), and submit the allergen uptake comparison data for FDA review and feedback prior to starting the STAMP study. The FDA’s explanation was that the results from the allergen uptake studies might affect the design of the STAMP study.
After careful review of the FDA’s information requests, in December 2021, the Company decided not to pursue the sequential approach to the development plans for Viaskin Peanut as requested by the FDA in the October 2021 feedback. The Company estimated that the FDA’s newly proposed sequential approach would require at least five rounds of exchanges that necessitate FDA alignment prior to initiating STAMP, the
6-month
safety and adhesion study. As such, in December 2021, the Company announced its plan to initiate a pivotal Phase 3 placebo-controlled efficacy trial for a modified Viaskin Peanut patch (mVP) in children in the intended patient population. The Company considers this approach the most straightforward to potentially demonstrate effectiveness, safety, and improved in vivo adhesion of the modified Viaskin Peanut system. The FDA confirmed the Company’s change in strategy is agreeable via oral and written exchanges.
On September 7, 2022, the Company announced the initiation of VITESSE, a new Phase 3 pivotal study of the modified Viaskin Peanut (mVP) patch in children ages
4-7
years with peanut allergy. We defined initiation as the submission of the trial protocol to selected study sites for subsequent Institutional Review Board (IRB)/Ethics Committee (EC) approval.
 
9

On September 21, 2022, the Company announced it received feedback from the U.S. FDA in the form of a partial clinical hold on VITESSE. In the partial clinical hold letter, the FDA specified changes to elements of the VITESSE protocol, acknowledging the intent for the trial to support a future BLA submission. In the following months, we engaged with the FDA to address the feedback provided in the partial clinical hold letter and to finalize the VITESSE protocol. In addition, we continued internal preparations for VITESSE and conducted certain site assessment and
start-up
activities for prompt study launch once the partial clinical hold was lifted.
On December 23, 2022, the Company announced the FDA lifted the partial clinical hold and confirmed the Company satisfactorily addressed all clinical hold issues. The FDA stated that VITESSE phase 3 clinical study may proceed with the revised trial protocol.
On March 2, 2023, the Company announced the completion of EVOLVE, a
12-week
caregiver and patient user experience study of the mVP patch in 50 peanut allergic children ages
4–11-years
old. The objective of EVOLVE was to evaluate the Instructions for Use (IFU) and ease of use for the mVP patch. The study concluded that the updated IFU supported correct patch application, which included no lifting of the patch edges or detachment directly after application. Furthermore, EVOLVE concluded that the majority of parents/caregivers reported a positive ease of use experience with the mVP patch. In EVOLVE, DBV also tested the functionality of an electronic patient diary (eDiary) to collect information on activities of daily living and patch adhesion scores. EVOLVE verified that the eDiary tool can be used by caregivers in VITESSE to capture the adhesion data in support of a potential BLA.
On March 7, 2023, the Company announced that the first patient was screened in the VITESSE study. Screening of the last patient is anticipated by the third quarter of 2024.
On April 19, 2023, the Company outlined the regulatory pathway for Viaskin Peanut in children
1-3
years old after the FDA confirmed that the Company’s Phase 3 EPITOPE study meets the
pre-specified
criteria for success for the primary endpoint, not requesting any additional efficacy study. The FDA required additional safety data to augment the safety data collected from EPITOPE in support of a BLA.
On July 31, 2023, the Company announced receipt of feedback from FDA on the two supplemental safety studies, COMFORT Children and COMFORT Toddlers. The COMFORT Toddlers safety study will enroll peanut allergic toddlers ages 1
3-years
and will support the efficacy results generated from the EPITOPE Phase 3 pivotal study. The COMFORT Children safety study will enroll peanut allergic children ages 4
7-years
and will support the efficacy results anticipated from the ongoing VITESSE Phase 3 pivotal study. FDA agreed with a
6-month
study duration and a 3:1 randomization (active:placebo) of approximately 400 subjects in the double-blind, placebo-controlled COMFORT Toddlers study. 
The Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1-through-3-year-olds to FDA on November 9, 2023, and the Company and FDA are still engaged in ongoing dialogue related to the program.
Viaskin Peanut for children ages
4-11—
European Union Regulatory History and Current Status
On August 2, 2021, the Company announced it received from the European Medicines Agency (EMA) the Day 180 list of outstanding issues, which is an established part of the prescribed EMA review process. It is a letter that is meant to include any remaining questions or objections at that stage in the process. The EMA indicated many of their objections and major objections from the Day 120 list of questions had been answered. One major objection remained at Day 180. The Major Objection questioned the limitations of the data, for example, the clinical relevance and effect size supported by a single pivotal study.
On December 20, 2021, the Company announced it withdrew the Marketing Authorization Application (MAA) for Viaskin Peanut and formally notified the EMA of our decision. The initial filing was supported by data from a single, placebo-controlled Phase 3 pivotal trial known as PEPITES
(V712-301).
The decision to withdraw was based on the view of EMA Committee for Medicinal Products for Human Use (CHMP) that the data available to date from a single pivotal clinical trial were not sufficient to preclude a Major Objection at Day 180 in the review cycle. The Company believes data from a second Viaskin Peanut pivotal clinical trial will support a more robust path for licensure of Viaskin Peanut in the EU. The Company intends to resubmit the MAA when that data set is available.
Viaskin Peanut for children ages
1-3
In June 2020, the Company announced that in Part A of the EPITOPE phase 3 clinical study, subjects in both treatment arms showed consistent treatment effects after 12 months of therapy, as assessed by a double-blind placebo-controlled food challenge and biomarker results. Part A subjects were not included in Part B and the efficacy analyses from Part A were not statistically powered to demonstrate superiority of either dose versus placebo. These results validate the ongoing investigation of the 250 µg dose in this age group, which is the dose being studied in Part B of the EPITOPE phase 3 clinical study. Enrollment for Part B of EPITOPE was completed in the first quarter of 2021.
 
10

In June 2022, the Company announced positive topline results from Part B of EPITOPE, which enrolled 362 subjects ages 1 to 3 years, of which 244 and 118 were in the active and placebo arms respectively. Enrollment was balance for age and baseline disease characteristics between the active and placebo treatment arms.
The Company intends to further analyze the data from EPITOPE and explore regulatory pathways for Viaskin Peanut in children ages
1
to
3
years, given the high unmet need and absence of approved treatments for this vulnerable population.
On April 19, 2023, the Company outlined the regulatory pathway for Viaskin Peanut in children
1-3
years old after the FDA confirmed that the Company’s Phase 3 EPITOPE study meets the
pre-specified
criteria for success for the primary endpoint, not requesting any additional efficacy study. The FDA requires additional safety data to augment the safety data collected from EPITOPE in support of a BLA. This new safety study will also generate patch adhesion data and will include updated instructions for use.
On May 10, 2023, the New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT) with VP was statistically superior to placebo in desensitizing children to peanut exposure by increasing the peanut dose that triggers allergic symptoms. As stated in an accompanying editorial piece, these data are seen as “very good news” for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years. Following this publication, the Company confirmed it is advancing regulatory efforts for VP in toddlers ages
1-3
years old with a confirmed peanut allergy.
In November 2023, the Company announced the interim analyses from the first year of the open-label extension of EPITOPE. These data were presented at the annual American College of Allergy, Asthma and Immunology (ACAAI) in November 2023.
The Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1-through-3-year-olds to FDA on November 9, 2023, and the Company and FDA are still engaged in ongoing dialogue related to the program.
Viaskin Peanut for Children ages
4-7
On September 7, 2022, the Company announced the initiation of VITESSE, a new Phase 3 pivotal study of the modified Viaskin Peanut (mVP) patch in children ages
4-7
years with peanut allergy.
The Company
defined initiation as the submission of the trial protocol to selected study sites for subsequent Institutional Review Board (IRB)/Ethics Committee (EC) approval.
On September 21, 2022, the Company announced we had received feedback from the FDA in the form of a partial clinical hold on VITESSE. In the partial clinical hold letter, the FDA specified changes to elements of the VITESSE protocol, acknowledging the intent for the trial to support a future BLA submission. In the following months,
the Company
engaged with the FDA to address the feedback provided in the partial clinical hold letter and to finalize the VITESSE protocol. In addition,
the Company
continued internal preparations for VITESSE and conducted certain site assessment and
start-up
activities for prompt study launch once the partial clinical hold was lifted.
On December 23, 2022, the Company announced the FDA lifted the partial clinical hold and confirmed we satisfactorily addressed all clinical hold issues. The FDA stated that VITESSE may proceed with the revised trial protocol.
On March 7, 2023, the Company announced that the first patient was screened in the VITESSE trial. Screening of the last patient is anticipated by
the third quarter of
2024.
In July 2023, the Company received Type C Meeting Written Responses from the FDA regarding key study design elements for COMFORT Children. In summary, there was an agreement with the Agency that COMFORT Children will be a Double-Blind, Placebo-Controlled study involving approximately 270 children, randomized at a 3:1 ratio (active to placebo). Participation will not necessitate a food challenge, and patch adhesion data will be generated using the same approach as previously agreed upon with the FDA for the VITESSE phase 3 study.
Subsequently, in October 2023, the Company received feedback from the FDA addressing the remaining protocol design elements for COMFORT Children. This feedback included language simplification for how Viaskin should be used. Furthermore, the key inclusion criteria for the COMFORT Children study will be based on a physician-diagnosed peanut allergy, peanut-specific IgE and a Skin Prick Test (with no requirement for a DBPCFC). The revised protocol design of the safety study was submitted to the FDA in Q4 2023. COMFORT Children is anticipated to be initiated towards the end of VITESSE enrollment. The Company intends that enrollment of the COMFORT Children safety study will be strategically timed to avoid competition with the VITESSE study for the same subjects.
Legal Proceedings
From time to time, the Company may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. The Company is not currently subject to any material legal proceedings.
Note 3: Cash and Cash Equivalents
The following tables summarize the cash and cash equivalents as of March 31, 2024 and December 31, 2023:
 
    
March 31,
    
December 31,
 
    
2024
    
2023
 
Cash
     15,725        10,530  
Cash equivalents
     85,800        130,836  
  
 
 
    
 
 
 
Total cash and cash equivalents as reported in the statements of financial position
  
 
101,525
 
  
 
141,367
 
  
 
 
    
 
 
 
 
11

    
March 31,
    
December 31,
 
    
2024
    
2023
 
Bank overdrafts
             
  
 
 
    
 
 
 
Total cash and cash equivalents as reported in the
statements
of cash flows
  
 
101,525
 
  
 
141,367
 
Cash equivalents are immediately convertible into cash at no or insignificant cost,
on
demand. They are measured using level 1 fair value measurements.
Note 4
:
Other Current Assets
Other current assets consisted of the following:
 
    
March 31,
    
December 31,
 
    
2024
    
2023
 
Research tax credit
     10,066        8,857  
Other tax claims
     5,725        5,236  
Prepaid expenses
     1,727        2,103  
Other receivables
     518        1,353  
  
 
 
    
 
 
 
Total
  
 
18,037
 
  
 
17,548
 
  
 
 
    
 
 
 
Research tax credit
The variance in Research Tax Credit is presented as follows:
 
    
Amount in

thousands of US

Dollars
 
Opening research tax credit receivable as of January 1, 2024
  
 
8,857
 
+ Operating revenue
     1,407  
- Payment received
      
- Adjustment and currency translation effect
     (198
  
 
 
 
Closing research tax credit receivable as of March 31, 2024
  
 
10,066
 
  
 
 
 
Of which -
Non-current
portion
      
Of which - Current portion
  
 
10,066
 
The other tax claims are primarily related to the VAT as well as the reimbursement of VAT that has been requested. Prepaid expenses are comprised primarily of insurance expenses, as well as legal and scientific consulting fees. Prepaid expenses also include upfront payments which are recognized over the term of the ongoing clinical studies.
 
12

Note 5
:
Lease contracts
Future minimum lease payments under the Company’s operating
leas
es’ right of use as of March 31, 2024 and December 31, 2023, are as follows:
 
    
March 31, 2024
   
December 31, 2023
 
    
Real estate
   
Other

assets
   
Total
   
Real estate
   
Other

assets
   
Total
 
Current portion
     344       61       405       1,205       71       1,275  
Year 2
     1,014             1,014       65       11       75  
Year 3
     1,259             1,259       421             421  
Thereafter
     6,256             6,256       5,515             5,515  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total minimum lease payments
  
 
8,873
 
 
 
61
 
 
 
8,934
 
 
 
7,205
 
 
 
81
 
 
 
7,295
 
Less: Effects of discounting
    (1,902     (7     (1,909     (1,617     (9     (1,626
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Present value of operating lease
  
 
6,971
 
 
 
54
 
 
 
7,025
 
   
5
,588
   
 
73
 
 
 
5,670
 
Less: current portion
     (178     (54     (232     (1,072  
    (72  
    (1,144  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Long-term operating lease
  
 
6,793
 
       
 
6,793
 
 
 
4,516
 
 
 
1
 
 
 
4,526
 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Weighted average remaining lease term (years)
     7.52       0.01       7.95       —     
Weighted average discount rate
     5.00     0.03  
      4.53     2.50  
 
The Company recognizes rent expense, calculated as the remaining cost of the lease allocated over the remaining lease term on a straight-line basis. Rent expense presented in the condensed consolidated statement of operations and comprehensive loss was:
 
    
March 31,
 
  
2024
    
2023
 
Operating lease expense / (income)
     586        446  
Net termination impact
     (12      (81
Supplemental cash flow information related to operating leases is as follows for the period March 31, 2024 and 2023:
 
    
March 31
 
  
2024
    
2023
 
Cash paid for amounts included in the measurement of lease liabilities
     
Operating cash flows for operating leases
     501        496  
Note 6: Trade Payables and Other Liabilities
6.1 Trade Payables
No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal period presented.
6.2 Other Current Liabilities
The following tables summarize the other current liabilities as of March 31, 2024 and December 31, 2023:
 
    
March 31
    
December 31,
 
    
2024
    
2023
 
    
Other
 current
liabilities
    
Other
 non-
current
liabilities
    
Total
    
Other
 current
liabilities
    
Other
 non-
current
liabilities
    
Total
 
Employee related liabilities
     4,629               4,629        7,828               7,828  
Tax liabilities
     180               180        223               223  
Other debts
     214               214        883               883  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
5,023
 
         
 
5,023
 
  
 
8,934
 
         
 
8,934
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
13

The Employee related liabilities include short-term debt to employees including social welfare and tax agency obligations as of March 31, 2024. The Employee related liabilities included short-term debt to employees including social welfare, tax agency obligations and bonus provision (paid during first quarter 2024)
as
of December 31, 2023.
Note 7: Shareholders’ equity
The share capital as of March 31, 2024 is set at the sum of €9,643,437 ($10,972 thousands converted at historical rates). It is divided into 96,434,369 fully authorized, subscribed and
paid-up
ordinary
shares with a par value of €0.10.
Note 8: Share-Based Payments
The Board of Directors has been authorized by the Shareholders General Meeting to grant restricted stock units (“RSU”), stock options (“SO”) and
non-employee
warrants (
Bons de Souscription d’Actions
or “BSA”).
During the three months ended March 31, 2024, the Company granted 262,000 stock options and 59,000 restricted stock units to employees.
There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 12 to the consolidated financial statements included in the Annual Report.
 
14

Change in Number of BSA/SO/RSU:
 
    
Number of outstanding
 
    
BSA
    
SO
    
RSUs
 
Balance as of December 31, 2023
  
 
244,693
 
  
 
7,129,541
 
  
 
2,021,370
 
Granted during the period
     —         262,000        59,000  
Forfeited during the period
     —         3,525        13,738  
Exercised/released duri
n
g the period
     —         —         2,598  
Expired during the period
     —         —         —   
  
 
 
    
 
 
    
 
 
 
Balance as of March 31, 2024
  
 
244,693
 
  
 
7,388,016
 
  
 
2,064,035
 
  
 
 
    
 
 
    
 
 
 
Share-based payments expenses reflected in the condensed consolidated statements of operations is as follows:
 
    
Three Months Ended

March 31,
 
    
2024
    
2023
 
Research & development
     SO        (513      (429
  
 
RSU
 
  
 
(256
  
 
(258
Sales & marketing
     SO        (23      (27
  
 
RSU
 
  
 
(9
  
 
(8
General & administrative
     SO        (1,030      (797
  
 
RSU
 
  
 
(126
  
 
(113
     
 
 
    
 
 
 
Total share-based compensation (expense)
     
 
(1,958
  
 
(1,632
     
 
 
    
 
 
 
The $0.3 million increase in share-based compensation expenses is notably due to the increase of number of ordinary share equivalents granted in 2023 impacting the three months ended March 31, 2024, in comparison to the number granted in 2022 impacting the three months ended March 31, 2023.
Note 9: Contingencies
The following tables summarize the contingencies as of March 31, 2024 and December 31, 2023:
 
    
March 31,
    
December 31,
 
    
2024
    
2023
 
Current contingencies
     3,153        3,959  
Non-current
contingencies
     965        935  
  
 
 
    
 
 
 
Total contingencies
  
 
4,118
 
  
 
4,894
 
  
 
 
    
 
 
 
The changes in contingencies are as follows:
 
    
Pension

retirement

obligations
    
Other

contingencies
    
Total
 
At January 1, 2024
  
 
935
 
  
 
3,959
 
  
 
4,894
 
Increases in liabilities
                    
Used liabilities
     —         (723      (723
Reversals of unused liabilities
     (8             (8
Net interest related to employee benefits, and unwinding of discount
     —         —          
Actuarial gains and losses on defined-benefit plans
     59        —         59  
Currency translation effect
     (20      (82      (103
  
 
 
    
 
 
    
 
 
 
At March 31, 2024
  
 
965
 
  
 
3,153
 
  
 
4,118
 
  
 
 
    
 
 
    
 
 
 
 
15

    
Pension

retirement

obligations
    
Other

contingencies
    
Total
 
Of which Current
  
 
— 
 
  
 
3,153
 
  
 
3,153
 
Of which
Non-current
  
 
965
 
  
 
 
  
 
965
 
In May 2016, the Company entered into a Development Collaboration and License Agreement (the “Collaboration Agreement”) with Société des Produits Nestlé S.A. (formerly NESTEC S.A.) (“NESTEC”) under which the Company was responsible for leading the development activities of MAG1C up through a pivotal phase 3 clinical program.
On October 30, 2023, the Company signed and NESTEC entered into a Mutual Termination Letter Agreement terminating the Collaboration Agreement.
As of March 31, 2024, the accrual for ongoing Clinical study completion totals $1.3 million (vs. $2.3 million as of December 31, 2023) representing our best estimate of the remaining expenses related to the ongoing clinical study.
The Company does not hold any plan assets related to long-term employee benefit for any of the periods presented. There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 14 to the consolidated financial statements included in the Annual Report.
Note 10: Operating income
The following table summarizes the operating income during the three months ended March 31, 2024 and 2023:
 
    
Three Months Ended

March 31,
 
    
2024
    
2023
 
Research tax credit
     1,407        1,765  
Other operating income
            429  
  
 
 
    
 
 
 
Total
  
 
1,407
 
  
 
2,194
 
  
 
 
    
 
 
 
As of March 31, 2023, other income were recorded according the Collaboration Agreement between the Company and NESTEC.
On October 30, 2023, the Company and NESTEC entered into a Mutual Termination Letter Agreement terminating the Collaboration Agreement, explaining the lack of other income as of March 31, 2024.
Note 11: Operating expenses
The Company had an average of 105 employees during the three months ended March 31, 2024, in comparison with an average of 87 employees during the three months ended March 31, 2023. This increase is mainly due to hiring to support clinical development activities related to ongoing and anticipated clinical trials and to support quality activities.
The following table summarizes the allocation of personnel expenses by function during the three months ended March 31, 2024 and 2023:
 
    
Three Months Ended

March 31,
 
    
2024
    
2023
 
Research and Development expenses
     5,048        4,006  
Sales and Marketing expenses
     334        165  
General and Administrative expenses
     3,236        3,100  
  
 
 
    
 
 
 
Total personnel expenses
  
 
8,618
 
  
 
7,272
 
  
 
 
    
 
 
 
 
16

The following table summarizes the allocation of personnel expenses by nature during the three months ended March 31, 2024 and 2023:
 
    
Three Months Ended

March 31,
 
    
2024
    
2023
 
Wages and salaries
     5,144        4,438  
Social security contributions
     1,207        699  
Expenses for pension commitments
     309        258  
Employer contribution to bonus shares
            244  
Share-based payments
     1,958        1,632  
  
 
 
    
 
 
 
Total
  
 
8,618
 
  
 
7,272
 
  
 
 
    
 
 
 
The increase in personnel expenses is mainly due to the recruitment of US employees.
Note 12: Financial income (expense)
Our financial income was $1.3 million for the three months ended March 31, 2024, compared to $0.6 million for the three
months
ended March 31, 2023. This item mainly includes the financial income on our financial assets.
Note 13: Commitments
There has been no significant change in other commitments from those disclosed in Note 17 to the consolidated financial statements included in the Annual Report.
Note 14: Relationships with Related Parties
There were no new significant related-party transactions during the period nor any change in the nature of the transactions from those described in Note 18 to the consolidated financial statements included in the Annual Report.
Note 15: Loss Per Share
Basic loss per share is calculated by dividing the net loss attributable to the shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. As the Company was in a loss position for each of the three months ended March 31, 2024 and 2023, the diluted loss per share is equal to basic loss per share because the effects of potentially dilutive shares were anti-dilutive as a result of the Company’s net loss.
The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three months ended March 31, 2024 and 2023 indicated in number of potential shares:
 
    
Three Months Ended

March 31,
 
    
2024
    
2023
 
Non-employee
warrants
     244,693        251,693  
Stock options
     7,388,016        5,318,569  
Restricted stock units
     2,064,035        1,583,938  
Prefunded warrants
     28,276,331        28,276,331
Note 16: Events after the Close of the Period
The Company evaluated subsequent events that occurred after March 31, 2024, through the date the condensed consolidated financial statements were issued after their approval by the Board of Directors on May 7, 2024 and determined that there are no significant events that require adjustments or disclosure in such condensed consolidated financial statements.
On April 22, 2024, the Company moved its headquarters to 107 Avenue de la République in Châtillon in France, which is subject to ratification by the shareholders of the Company at the annual general meeting on May 16, 2024.
 
 
17


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part 1, Item 1 of this Report and with our audited financial statements and related notes thereto for the year ended December 31, 2023, included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 7, 2024, or the Annual Report. This discussion and other parts of this Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause such differences are discussed in the section of this Report titled “Special Note Regarding Forward-Looking Statements” and under “Item 1A. Risk Factors” in the Annual Report.

Overview

We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). We have generated significant data demonstrating that Viaskin’s mechanism of action is novel and differentiated. Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. We are advancing this unique technology to treat children suffering from food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. We believe Viaskin may offer convenient, self-administered, non-invasive immunotherapy to patients, if approved.

Our most advanced product candidate is Viaskin Peanut, which has been evaluated as a potential therapy for children with peanut allergy in eleven clinical trials, including four Phase 2 trials and four completed Phase 3 trials. We also have an ongoing Phase 3 trial of Viaskin Peanut in children ages four to seven with peanut allergy, as well as two planned Phase 3 supplementary safety studies, one in peanut-allergic children ages four through seven, and one in peanut-allergic toddlers, ages one through three.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the revenue, costs and expenses recognized during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no new policies or significant changes to our critical accounting policies as disclosed in the critical accounting policies described in the Annual Report. Our significant accounting policies are more fully described in Note 1 of the Notes to the Consolidated Financial Statements in Part I, Item 1 of our Annual Report.

Business trends and Results of Operations

Comparison of the Three Months Ended March 31, 2024 and 2023

The following table summarizes our results of operations, derived from our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars, for the three months ended March 31, 2024 and 2023.

 

18


     Three months ended
March 31,
               
     2024      2023      $ change      % change  

Operating income

   $ 1,407      $ 2,194        (787      (36 %) 

Operating expenses

           

Research and development expenses

     (21,403      (16,037      (5,366      33

Sales and marketing expenses

     (758      (434      (324      75

General and administrative expenses

     (7,804      (6,889      (915      13
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Operating expenses

     (29,964      (23,359      (6,605      28
  

 

 

    

 

 

    

 

 

    

 

 

 

Financial income

     1,261        605        656        108
  

 

 

    

 

 

    

 

 

    

 

 

 

Income tax

     (48      —         (48      —   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss

   $ (27,345    $ (20,561      (6,785      33
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic/diluted Net loss per share attributable to shareholders

   $ (0.28    $ (0.22      

Operating Income

The following table summarizes our operating income during the three months ended March 31, 2024 and 2023:

 

     Three months ended
March 31,
     $ change      % change  
     2024      2023                

Sales

     —         —         —         —   

Other income

     1,407        2,194        (787      (36 %) 

Research tax credit

     1,407        1,765        (358      (20 )% 

Other operating income

     —         429        (429      (100 %) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating income

     1,407        2,194        (787      (36 %) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Until the end of 2023, our operating income was composed of both the French research tax credit (Crédit d’Impôt Recherche, or “CIR”) and the revenue recognized under the Collaboration Agreement with NESTEC. Following the termination of the Collaboration Agreement on October 30, 2023, our operating income is now exclusively generated by the French research tax credit.

Operating Expenses

Since inception, our operating expenses have consisted primarily of research and development activities, and to a lower extent general and administration sales and marketing activities.

 

19


Research and Development Expenses

The following table summarizes our research and development expenses incurred during the three months ended March 31, 2024 and 2023:

 

     Three Months Ended
March 31,
               
Research and Development expenses    2024      2023      $ change      % change  

External clinical-related expenses

     14,026        10,471        3,555        34

Employee-related costs

     4,278        3,319        959        29

Share-based payment expenses

     770        687        83        12

Depreciation, amortization and other costs

     2,329        1,559        770        69
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Research and Development expenses

     21,403        16,037        5,366        33
  

 

 

    

 

 

    

 

 

    

 

 

 

Research and Development expenses increased by $5.4 million for the three months ended March 31, 2024, compared to the three

months ended March 31, 2023, primarily due to the increase in external clinical-related expenses for $3.6 million, driven by progress on patient enrollment in VITESSE Phase 3 clinical trial.

Employee-related costs, excluding share-based payments, increased by $1.0 million for the three months ended March 31, 2024 compared to the three months ended March 31, 2023 due to the recruitment of employees to support research and development activities mainly on the VITESSE trial.

Sales and Marketing expenses

The following table summarizes our sales and marketing expenses incurred during the three months ended March 31, 2024 and 2023:

 

     Three Months Ended
March 31,
     $ change      % change  
Sales and Marketing expenses    2024      2023  

Personnel expenses (incl. share-based payment expenses)

     334        165        169        102

External professional services and other costs

     424        269        155        58
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Sales and Marketing expenses

     758        434        324        75
  

 

 

    

 

 

    

 

 

    

 

 

 

Sales and marketing expenses have increased by $0.3 million during the three months ended March 31, 2024, compared the three months ended March 31, 2023 to support pre-commercialization activities for Viaskin Peanut in North America.

General and Administrative expenses

The following table summarizes our general and administrative expenses incurred during the three months ended March 31, 2024 and 2023:

 

     Three Months Ended
March 31,
     $ change      % change  
General and Administrative expenses    2024      2023  

External professional services

     2,433        1,706        726        43

Employee-related costs

     2,080        2,190        (111      (5 %) 

Share-based payment expenses

     1,157        910        247        27

Depreciation, amortization and other costs

     2,135        2,082        53        3
  

 

 

    

 

 

    

 

 

    

 

 

 

Total General and Administrative expenses

     7,804        6,889        915        13 % 
  

 

 

    

 

 

    

 

 

    

 

 

 

General and Administrative expenses increased by $0.9 million for the three months ended March 31, 2024, compared to the three months ended March 31, 2023 as a result of external professional services incurred to prepare financing activities as well to perform recruitments.

 

20


Financial income (expense)

Our financial income was $1.3 million for the three months ended March 31, 2024, compared to a financial income of $0.6 million for the three months ended March 31, 2023. This item mainly includes the financial income on our financial assets.

This item mainly includes the financial income on our financial assets, reflecting the rise of Euro short term monetary rates between 2023-Q1 (€STER = 1.89% on December 31, 2022) and 2024-Q1 (€STER = 3.88% on December 31, 2023), where our excess cash is invested.

Income tax

Our income tax profit for the three months ended March 31, 2024 was $48 thousand. We did not have any income tax profit or expense for the three months ended March 31, 2023.

Net loss

Net loss was $27.3 million for the three months ended March 31, 2024, compared to $20.6 million for the three months ended March 31, 2023. Net loss per share (based on the weighted average number of shares outstanding over the period) was $0.28 and $0.22 for the three months ended March 31, 2024 and 2023, respectively.

Liquidity and Capital Resources

Financial Condition

On March 31, 2024, we had $101.5 million in cash and cash equivalents compared to $141.4 million of cash and cash equivalents on December 31, 2023. Based on its current operations, plans and assumptions, the Company expects that its balance of cash and cash equivalents will be sufficient to fund its operations until December 31, 2024.

As of the date of filing, our available cash is not projected to be sufficient to support our operating plan for at least the next 12 months. As such, there is substantial doubt regarding our ability to continue as a going concern.

We have incurred operating losses and negative cash flows from operations since our inception. Net cash used for operating activities was $34.7 million and $20.8 million for the three months ended March 31, 2024 and 2023, respectively. For the three months ended March 31, 2024, we recorded a net loss of $27.3 million. Our net cash flows provided by financing activities was $(0.1) million during the three months ended March 31, 2024 compared to a nil amount during the three months ended March 31, 2023. Our net cash flows used in investing activities was $(2.1) million during the three months ended March 31, 2024, including revamping of the new headquarter for $(1.3) million, compared to $(0.1) million during the three months ended March 31, 2023.

Our financial statements have been prepared on a going concern basis assuming that we will be successful in our financing objectives. As such, no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should we not be able to continue as a going concern.

Sources of Liquidity and Material Cash Requirements

We have incurred net losses each year since our inception. Substantially all of our net losses resulted from costs incurred in connection with our development programs and from general and administrative expenses associated with our operations. We have not incurred any bank debt.

We fund short-term cash requirements primarily from payments associated with research tax credits (Crédit d’Impôt Recherche).

In May 2022, we established an At-The-Market (“ATM”) program to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $100 million of American Depositary Shares (“ADSs”), each ADS representing one-half of one ordinary share of the Company. The ATM program is intended to be effective through the expiration of the Company’s existing registration statement registering the ADSs to be issued under the ATM program, i.e. until July 16, 2024, unless terminated prior to such date in accordance with the sales agreement or the maximum amount of the program has been reached. The Company’s intent is to use the net proceeds, if any, of sales of ADSs issued under the program, together with its existing cash and cash equivalents, primarily for activities associated with potential approval and launch of Viaskin Peanut, as well as to advance the development of the Company’s product candidates using its Viaskin Platform and for working capital and other general corporate purposes.

 

21


We intend to seek additional capital as we prepare for the launch of Viaskin Peanut, if approved, and continue other research and development efforts. We may seek to finance our future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of non-dilutive financings.

We cannot guarantee that we will be able to obtain the necessary financing to meet our needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to us, including reduced ability to raise additional capital when needed or on acceptable terms, if at all. If we are not successful in our financing objectives, we could have to scale back our operations, notably by delaying or reducing the scope of our research and development efforts or obtain financing through arrangements with collaborators or others that may require us to relinquish rights to our product candidates that we might otherwise seek to develop or commercialize independently.

Operating leases

At the date of filing, our corporate headquarters are located in Châtillon, France. Our principal offices occupy a 2,447 square meter facility, pursuant to a lease agreement dated November, 2023 and represents a $4.5 million cash requirement as of March 31, 2024 until March, 2033. The move of the corporate headquarters to Châtillon, France is subject to ratification by the shareholders of the Company at the annual general meeting on May 16, 2024.

The lease agreement for the office occupying 4,470 square meter facility in Montrouge, France, signed on March 3, 2015, with an effective date of August 1, 2025, expires on May, 2024. Associated lease termination costs were reflected in the Company’s financial accounts in the Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 7, 2024.

At the date of filing, our primary U.S. office is located in Warren, New Jersey. In February 2024, we entered into a sublease agreement, commencing on March 19, 2024 and effective for 70 months, for an office of 16,704 square feet in Warren, New Jersey. The Warren office represent a $1.8 million cash requirement as of March 31, 2024 which expires December 31, 2029.

We also have facilities in North America that were intended to support our U.S. operations. We lease 5,799 square feet in Basking Ridge, New Jersey, which commenced on April 1, 2022 and is effective for 38 months.

The Company transitioned to its new offices location in Warren NJ and Châtillon France over the end of the first quarter of 2024. Leases from prior offices located in Basking Ridge NJ and Montrouge, France offices were still active at the time of filing.

There have been no material changes in our operating leases from those disclosed in the Annual Report.

Purchase obligations—Obligations Under the Terms of CRO Agreements

In connection with the launch of our clinical trials for Viaskin Peanut and Viaskin Milk, we signed agreements with several contract research organizations. As of December 31, 2023, expenses associated with the ongoing trials amounted globally to $114.4 millions, and we had non-cancellable contractual obligations with CRO until year ended 2025 amounting to $64.4 millions.

There have been no material changes in our purchase obligations from those disclosed in the Annual Report.

Summary Statement of Cash Flows

The table below summarizes our sources and uses of cash for the three months ended March 31, 2024 and 2023.

 

     Three months ended
March 31,
               
(Amounts in thousands of U.S. Dollars)    2024      2023      $ change      % of
change
 

Net cash flow provided by (used in) operating activities

     (34,692      (20,841      (13,851      66

Net cash flow provided by (used in) investing activities

     (2,132      42        (2,174      (5,176 %) 

Net cash flow provided by (used in) financing activities

     (62      (14      (47      328

Effect of exchange rate changes on cash and cash equivalents

     (2,957      3,909        (6,866      (176 %) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Net (decrease) increase in cash and cash equivalents

     (39,842      (16,905      (22,937      136
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating Activities

Our net cash flows used in operating activities were $34.7 million and $20.8 million during the three months ended March 31, 2024 and 2023, respectively. The variance of $13.9 million is mainly driven by the increase in (1) external clinical-related expenses by $3.7 million, (2) R&D activities to support clinical trials progress through Regulatory Affairs, Medical Affairs, Manufacturing platform and Supply activities by $6.4 million and (3) internal employees’ compensation increase by $2.5 million with 18 additional employees.

 

22


Investing Activities

Our net cash flows used in investing activities was $(2.1) million during the three months ended March 31, 2024, including revamping of the new offices in Châtillon, France for $(1.3) million, compared to $(0.1) million during the three months ended March 31, 2023.

Smaller Reporting Company Status

We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended. We may, and intend to, take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as we are a smaller reporting company. We may be a smaller reporting company in any year in which (i) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) (a) our annual revenue is less than $100.0 million during the most recently completed fiscal year and (b) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Based on its evaluation as of March 31, 2024, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) were effective to provide reasonable assurance that (i) the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitation on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error of fraud may occur and not be detected.

 

23


PART II – Other information
Item 1. Legal Proceedings
See “Note 2: Significant Events and Transactions – Legal Proceedings” in the notes to the condensed consolidated financial statements included elsewhere in this Quarterly Report.
Item 1A. Risk Factors
Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and trading price of our securities. In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report. There have been no material changes in our risk factors from those disclosed in the Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
During the three months ended March 31, 2024, we issued the following unregistered securities:
 
   
On March 23, 2024, the issuance of an aggregate of 2,599 ordinary shares to US and
non-US
employees upon settlement of RSUs.;
None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe these transactions were exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Regulation S promulgated under Section 5 of the Securities Act, as transactions by an issuer not involving any public offering or as offerings made to
non-U.S.
resident employees pursuant to an employee benefit plan established and administered in accordance with the law of a country other than the United States (namely, the Republic of France) and in accordance with that country’s practices and documentation. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
During the three months ended March 31, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated any contracts, instructions or written plans for the purchase or sale of the Company’s securities.
 
24


Item 6. Exhibits.

Exhibit Index

 

          Incorporated by Reference  

Exhibit

  

Description

   Schedule/ Form      File Number      Exhibit      File Date  

3.1

   By-laws (status) of the registrant (English translation)            

31.1

   Certificate of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as Amended            

31.2

   Certificate of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended            

32.1*

   Certificate of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended            

101.INS

   XBRL Instance Document            

101.SCH

   XBRL Taxonomy Extension Schema Document            

101.CAL

   XBRL Taxonomy Extension Calculation Linkbase Document            

101.DEF

   XBRL Taxonomy Extension Definition Linkbase Document            

101.LAB

   XBRL Taxonomy Extension Labels Linkbase Document            

101.PRE

   XBRL Taxonomy Extension Presentation Linkbase Document            

104

   Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.            

 

*

Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, (whether made before or after the date of the Form 10-Q), irrespective of any general incorporate language contained in such filing.

 

25


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    DBV Technologies S.A.
    (Registrant)
Date: May 7, 2024     By:  

/s/ Daniel Tassé

    Daniel Tassé
    Chief Executive Officer
    (Principal Executive Officer)
Date: May 7, 2024     By:  

/s/ Virginie Boucinha

    Virginie Boucinha
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

26